ORCL vs VEEV: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
ORCL is the larger of the two ($374.09B market cap): the incumbent the market prices for continued execution (11.93x forward earnings, beta 1.71). VEEV is the smaller challenger ($33.10B), actually pricier on forward earnings (20.31x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ORCL vs VEEV: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ORCL | VEEV | What it tells you |
|---|---|---|---|
| Market cap | $374.09B | $33.10B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.93 | 20.31 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 22.28 | 36.13 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.71 | 0.94 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 7% of range | 34% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 9.96 | 4.55 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ORCL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ORCL and VEEV affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ORCL and VEEV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ORCL and VEEV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Oracle (ORCL) do?
Oracle is one of the largest enterprise software companies in the world. The traditional business is database software (the Oracle Database is the dominant enterprise relational database), enterprise applications (Oracle ERP, HCM, CRM via the Fusion suite, plus NetSuite for smaller businesses), and Java (Oracle owns and maintains the Java platform). These are mature, sticky, high-margin businesses.
What does Veeva Systems (VEEV) do?
Veeva Systems Inc. is the dominant provider of cloud software built specifically for the life-sciences industry, serving pharmaceutical, biotech, and medical-device companies. Its products span two broad areas: commercial applications, including its CRM used by drug-company sales and medical teams, and its Vault platform, a content and data-management system used across clinical trials, regulatory submissions, quality, and safety. Because Veeva's software is purpose-built for the highly regulated life-sciences world and is deeply embedded in customers' core workflows, it enjoys strong retention and pricing power, and it earns recurring subscription revenue.
ORCL vs VEEV: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ORCL drivers: Oracle Cloud Infrastructure (OCI) AI deals; Database and applications as the cash cow.
- VEEV drivers: Life-sciences market dominance; Vault CRM transition.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: AI cloud deals carry execution risk: massive datacenter buildouts must be delivered on time, profitably. For VEEV, the dominant risk is valuation: as a high-quality software company, Veeva trades at a premium multiple that assumes durable growth, so any slowdown in revenue or the Vault CRM migration could pressure the stock.
ORCL or VEEV: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ORCL if you believe its drivers more; VEEV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ORCL and VEEV guides.
ORCL vs VEEV: the full fundamentals
ORCL. Oracle's valuation has re-rated meaningfully higher as the market has come to view it as an AI cloud beneficiary rather than just a legacy database company. The multiple expansion is justified if AI cloud bookings continue; it compresses quickly if growth stalls.
VEEV. Figures are approximate and tied to the asOf date; verify live numbers before acting. Unlike many unprofitable software names, Veeva has real earnings, so investors look at both its P/E and growth-adjusted metrics, plus revenue growth, operating margins, and free cash flow. The stock carries a premium valuation that embeds expectations of steady mid-teens growth, a successful Vault CRM transition, and expanding AI adoption. That premium means the shares can fall on any growth disappointment even though the underlying business is high quality.
Headline figures (approximate, early 2026): ORCL shows revenue (ttm) ~$58 billion, operating margin ~30% (compressed by AI capex), net income (ttm) ~$13 billion, eps (ttm) ~$4.50; VEEV shows fy2026 revenue Roughly $3.2 billion, up about 16% year over year, q4 fy2026 revenue Around $836 million, up about 16% and ahead of estimates, profitability Highly profitable with strong operating margins and robust free cash flow, vault crm traction More than 150 customers live, dozens of migrations completed, high win rate.
The bottom line: ORCL vs VEEV
ORCL and VEEV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ORCL and VEEV exposure against your real portfolio. It is not an investment adviser.
Wondering how ORCL or VEEV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Oracle with AI
Connect the broker you already use and ask Walnut's AI how ORCL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ORCL and VEEV?
+
Oracle is one of the largest enterprise software companies in the world. Veeva Systems Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ORCL or VEEV the better stock?
+
Neither is universally better. ORCL is the larger incumbent; VEEV is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ORCL or VEEV?
+
On forward P/E (as of August 2026), ORCL trades at 11.93x and VEEV at 20.31x, so ORCL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ORCL and VEEV?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ORCL vs VEEV?
+
ORCL: AI cloud deals carry execution risk: massive datacenter buildouts must be delivered on time, profitably. If AI capex demand cools, the buildout becomes a stranded asset risk. VEEV: The dominant risk is valuation: as a high-quality software company, Veeva trades at a premium multiple that assumes durable growth, so any slowdown in revenue or the Vault CRM migration could pressure the stock. Veeva's fortunes are concentrated in a single industry, so any downturn in life-sciences spending, tighter drug-industry budgets, or pharma R&D pullbacks would hit it more than a diversified software vendor. The CRM transition itself carries execution risk, and unwinding its historical relationship with Salesforce introduces competitive dynamics, as Salesforce and others could target the same customers. Regulatory change in the drug industry, biotech funding cycles, and consolidation among pharma customers can affect demand. AI is an opportunity but also a competitive threat if rivals or in-house tools erode Veeva's advantages. Currency swings and stock-based compensation are additional considerations. Overall, Veeva is a strong business, but its premium price leaves limited room for disappointment.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ORCL or VEEV; figures are approximate and dated (as of August 2026). Verify current data before investing.